Literature DB >> 3971482

The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy.

A L Stewart, J M Margison, P M Wilkinson, S B Lucas.   

Abstract

An unambiguous and specific HPLC assay was used to determine the pharmacokinetics of 7-hydroxymethotrexate (7-OHMTX) following the administration of moderate-dose methotrexate (MTX) 100 mg X m-2 to 37 patients with advanced head and neck cancer. There was marked interpatient variation but patient exposure to 7-OHMTX was considerable. There was, however, no correlation between the amount of 7-OHMTX produced and either tumour response or patient toxicity.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3971482     DOI： 10.1007/bf00434358

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  5 in total

1.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

2.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

3.  Dose-dependent metabolism of methotrexate in man and rhesus monkeys.

Authors:  S A Jacobs; R G Stoller; B A Chabner; D G Johns
Journal:  Cancer Treat Rep       Date:  1977-07

4.  7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.

Authors:  S A Jacobs; R G Stoller; B A Chabner; D G Johns
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

5.  The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy.

Authors:  J Lankelma; E van der Klein; F Ramaekers
Journal:  Cancer Lett       Date:  1980-04       Impact factor: 8.679
  5 in total
  6 in total

1.  Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.

Authors:  Markus Joerger; Andrés J M Ferreri; Stephan Krähenbühl; Jan H M Schellens; Thomas Cerny; Emanuele Zucca; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

2.  Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

Authors:  M Joerger; A D R Huitema; H J G D van den Bongard; P Baas; J H Schornagel; J H M Schellens; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

3.  Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate.

Authors:  P Sonneveld; F W Schultz; K Nooter; K Hählen
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 4.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

Review 5.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651

6.  Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-21       Impact factor: 2.745
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.